<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MAP2 Protein</th>
</tr>
<tr>
<td class="label">Protein Symbol</td>
<td>MAP2</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Microtubule-Associated Protein 2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MAP-2, MAP2A, MAP2B, MAP2C, MAP2D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q34-q35</td>
</tr>
<tr>
<td class="label">Entrez Gene ID</td>
<td>4135</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P29536</td>
</tr>
<tr>
<td class="label">Isoforms</td>
<td>Multiple (MAP2A, MAP2B, MAP2C, MAP2D)</td>
</tr>
<tr>
<td class="label">Tissue Specificity</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal projection domain</td>
<td>1-1500 aa</td>
</tr>
<tr>
<td class="label">Microtubule-binding domain</td>
<td>1500-1800 aa</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>1800-2000+ aa</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Molecular Weight</td>
</tr>
<tr>
<td class="label">MAP2A</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">MAP2B</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">MAP2C</td>
<td>~70 kDa</td>
</tr>
<tr>
<td class="label">MAP2D</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">Dendritic localization<
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MAP2 Protein</th>
</tr>
<tr>
<td class="label">Protein Symbol</td>
<td>MAP2</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Microtubule-Associated Protein 2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MAP-2, MAP2A, MAP2B, MAP2C, MAP2D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q34-q35</td>
</tr>
<tr>
<td class="label">Entrez Gene ID</td>
<td>4135</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P29536</td>
</tr>
<tr>
<td class="label">Isoforms</td>
<td>Multiple (MAP2A, MAP2B, MAP2C, MAP2D)</td>
</tr>
<tr>
<td class="label">Tissue Specificity</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal projection domain</td>
<td>1-1500 aa</td>
</tr>
<tr>
<td class="label">Microtubule-binding domain</td>
<td>1500-1800 aa</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>1800-2000+ aa</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Molecular Weight</td>
</tr>
<tr>
<td class="label">MAP2A</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">MAP2B</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">MAP2C</td>
<td>~70 kDa</td>
</tr>
<tr>
<td class="label">MAP2D</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">Dendritic localization</td>
<td>Concentrated in dendritic shafts and spines</td>
</tr>
<tr>
<td class="label">Spine morphology</td>
<td>Regulates dendritic spine shape and stability</td>
</tr>
<tr>
<td class="label">Synaptic targeting</td>
<td>Localizes to postsynaptic densities</td>
</tr>
<tr>
<td class="label">Signal transduction</td>
<td>Scaffold for signaling molecules</td>
</tr>
<tr>
<td class="label">Change</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Reduced immunoreactivity</td>
<td>Decreased MAP2 staining</td>
</tr>
<tr>
<td class="label">Dendritic degeneration</td>
<td>Beading, fragmentation</td>
</tr>
<tr>
<td class="label">Colocalization with plaques</td>
<td>MAP2 around amyloid</td>
</tr>
<tr>
<td class="label">Correlation with cognition</td>
<td>MAP2 loss tracks dementia</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>MAP2 Relationship</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Reduced MAP2 in striatal neurons</td>
</tr>
<tr>
<td class="label">Frontotemporal dementia</td>
<td>Tau pathology affects MAP2</td>
</tr>
<tr>
<td class="label">Multiple sclerosis</td>
<td>Marker of demyelination damage</td>
</tr>
<tr>
<td class="label">Traumatic brain injury</td>
<td>MAP2 as injury biomarker</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Microtubule disruption</td>
<td>Loss of stabilization leads to transport defects</td>
</tr>
<tr>
<td class="label">Synaptic loss</td>
<td>Reduced synaptic MAP2 precedes neuron death</td>
</tr>
<tr>
<td class="label">Phosphorylation imbalance</td>
<td>Abnormal kinases/phosphatases affect MAP2</td>
</tr>
<tr>
<td class="label">Proteasomal degradation</td>
<td>Increased MAP2 cleavage in disease</td>
</tr>
<tr>
<td class="label">Biomarker Use</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Neuronal injury</td>
<td>CSF/serum MAP2</td>
</tr>
<tr>
<td class="label">Disease progression</td>
<td>Brain MAP2 loss</td>
</tr>
<tr>
<td class="label">Therapeutic monitoring</td>
<td>MAP2 recovery</td>
</tr>
<tr>
<td class="label">Autopsy tissue</td>
<td>MAP2 immunostaining</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">β-Tubulin</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Competition</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>Scaffold binding</td>
</tr>
<tr>
<td class="label">NMDA receptor</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MARK kinases</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Fyn kinase</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Region</td>
<td>MAP2 Expression</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Very high (CA1-CA3, dentate gyrus)</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>High (layers II-VI)</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate (Purkinje cell dendrites)</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Site</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Multiple serine/threonine</td>
</tr>
<tr>
<td class="label">PKA</td>
<td>Serine residues</td>
</tr>
<tr>
<td class="label">MARK/PAR-1</td>
<td>KXGS motifs</td>
</tr>
<tr>
<td class="label">GSK-3β</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">CDK5</td>
<td>Proline-directed sites</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">140 edges</a></td>
</tr>
</table>
MAP2 (Microtubule-Associated Protein 2) is a neuronal cytoskeletal protein that plays critical roles in stabilizing microtubules, maintaining dendritic architecture, and regulating synaptic function. As one of the most abundant proteins in neurons, MAP2 is essential for proper neuronal development, axonal transport, and plasticity. It serves as a key biomarker for neuronal injury and is heavily implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. [@shafitzagardo1999]
MAP2 is a large protein with distinct structural domains:
The MAP2 gene produces multiple isoforms through alternative splicing:
MAP2 contains 3-4 repeat sequences in its microtubule-binding domain:
Repeat 1: 1766-1790 aa
Repeat 2: 1791-1815 aa
Repeat 3: 1816-1840 aa
Repeat 4 (if present): 1841-1865 aa
These repeats bind to the C-terminal tails of β-tubulin, stabilizing microtubule structure.
MAP2's primary function is stabilizing neuronal microtubules:
MAP2 is specifically enriched in dendrites (not axons):
MAP2 plays essential roles at synapses:
MAP2 is intimately involved in AD pathogenesis:
MAP2 participates in several key pathways:
Map2 knockout mice exhibit: